Composition for preventing or treating diabetic skin disease comprising exosomes derived from thrombin-treated stem cells

Abstract

The present invention relates to a pharmaceutical composition for preventing or treating diabetic skin diseases, comprising exosomes derived from thrombin-treated stem cells as an active ingredient, a pharmaceutical formulation containing the composition, and a method for preparing the same. In the present invention, exosomes isolated from thrombin-treated stem cells were confirmed to be highly effective in improving diabetic skin disorders in diabetic animal models. Furthermore, exosome-based therapeutic agents are cell-free, meaning they contain no DNA and therefore have low risk of carcinogenesis. They also lack cell surface antigens, meaning they are safe and do not pose the risk of transplant rejection. Furthermore, because they are isolated substances rather than cells, they can be developed as off-the-shelf products, reducing manufacturing costs. Therefore, the thrombin-treated stem cell-derived exosomes of the present invention are expected to be developed as therapeutic agents for various intractable chronic skin diseases induced by diabetes and to be useful in fields related to skin regeneration.

Description

[Technical field]

[0001] The present invention relates to a pharmaceutical composition for preventing or treating diabetic skin diseases, comprising exosomes isolated from thrombin-treated stem cells as an active ingredient, a pharmaceutical preparation containing the composition, and a method for producing the same. [Background technology]

[0002] Diabetes is a metabolic disease characterized by insufficient or non-functioning insulin secretion and is characterized by hyperglycemia, which is an increase in the concentration of glucose in the blood, and causes various symptoms and signs due to hyperglycemia, and glucose is excreted in the urine. Type 1 diabetes, also known as "childhood diabetes," occurs when pancreatic beta cells are destroyed by an autoimmune mechanism, resulting in absolute or relative deficiency of insulin production, while type 2 diabetes is induced by insulin resistance and is known to occur due to a variety of factors, including obesity, decreased insulin receptors, decreased insulin secretion, and genetic factors.

[0003] According to a 2016 announcement by the Korea Diabetes Society, the prevalence of diabetes among the adult population aged 30 and over in Korea in 2014 reached an all-time high of 13.7%, and the risk of diabetes-related diseases is also at a serious level, with the prevalence of obesity and abdominal obesity among diabetic patients reaching 48.6% and 58.9%, respectively, and hypertension and hypercholesterolemia occurring in 54.7% and 31.6%, respectively. Thus, diabetes not only poses risks in itself, but also causes serious complications such as cardiovascular disease, retinopathy, kidney failure, peripheral nerve complications, and skin diseases.

[0004] Diabetic skin disease, one of the diseases induced by diabetes, is caused by high blood glucose levels in diabetic patients for a long time, and specifically includes diabetic ulcers, acanthosis nigricans, diabetic necrobiosis lipoidica, diabetic skin disorders, eruptive xanthomas, soft fibroma, pruritus, granuloma annulare, bacterial and fungal infections, etc. In particular, skin disorders can become chronic diseases because they do not recover sufficiently due to high blood glucose levels. Therefore, it is necessary to develop an effective formulation that can prevent and treat various skin disorders induced by diabetes.

[0005] Meanwhile, stem cells are known to be involved in tissue regeneration, healing, and immune responses due to their pluripotency. Taking advantage of these characteristics, there have been efforts to isolate and culture mesenchymal stem cells from umbilical cord blood, bone marrow, etc., and develop them as treatments for various diseases and symptoms.

[0006] However, such a treatment using stem cells itself has the following limitations and side effects. First, cell therapy agents cannot eliminate the possibility of tumorigenicity due to DNA transfer. Second, stem cells themselves can induce vascular obstruction and myocardial infarction due to their large size. Third, when using allogeneic cells such as umbilical cord blood for transplantation (allotransplantation), there is a problem of rejection due to cell surface antigens. Fourth, cell therapy agents generally have limitations in that the manufacturing process is difficult and there are many restrictions on storage and transportation, resulting in high production costs. As a way to improve the therapeutic effect while reducing side effects due to the basic limitations of stem cells, a method of improving efficacy using genetic manipulation has been developed, but there is currently no clear alternative.

[0007] Exosomes are small vesicles (approximately 30-100 nm in diameter) with a membrane structure secreted from various cells. In electron microscopy, it was observed that they do not detach directly from the plasma membrane, but originate from specific intracellular compartments called multivesicular bodies (MVBs) and are released and secreted outside the cell. In other words, when fusion of the multivesicular body with the plasma membrane occurs, the vesicles are released into the extracellular environment, which are called exosomes. Although the molecular mechanism by which such exosomes are produced has not been clearly elucidated, it has been known that not only red blood cells but also various types of immune cells including B lymphocytes, T lymphocytes, dendritic cells, platelets, macrophages, etc., as well as tumor cells and stem cells, produce and secrete exosomes in their living state.

[0008] In particular, exosomes derived from stem cells contain not only receptors and proteins but also nuclear components and are known to play a role in intercellular communication. In addition, exosomes derived from stem cells contain relatively less animal serum compared to stem cells, eliminating the risk of zoonosis caused by animal serum infection. Considering these characteristics of exosomes, cell therapy using exosomes is expected to become a new paradigm that can overcome the limitations of conventional stem cell therapy.

[0009] In this regard, the therapeutic effect of diabetic skin ulcers using pluripotent stem cells has been disclosed (KR10-2018-0104196), but the therapeutic use of thrombin-treated stem cell-derived exosomes for diabetic skin diseases is not known. Summary of the Invention [Problem to be solved by the invention]

[0010] The present inventors have conducted research into the application of exosomes derived from stem cells to diabetic skin diseases, and as a result, have confirmed excellent therapeutic effects of the exosomes when skin lesions are induced in a diabetic animal model, as an example of diabetic skin disease. Based on this, the present invention has been completed.

[0011] Accordingly, an object of the present invention is to provide a pharmaceutical composition for preventing or treating diabetic skin diseases, comprising thrombin-treated stem cell-derived exosomes as an active ingredient.

[0012] Another object of the present invention is to provide a pharmaceutical preparation for treating diabetic skin diseases, comprising the pharmaceutical composition.

[0013] Yet another object of the present invention is to provide a quasi-drug preparation for improving diabetic skin diseases, comprising thrombin-treated stem cell-derived exosomes.

[0014] It is yet another object of the present invention to provide a method for preparing the pharmaceutical composition. [Means for solving the problem]

[0015] In order to achieve the above-mentioned objects of the present invention, the present invention provides a pharmaceutical composition for preventing or treating diabetic skin diseases, comprising thrombin-treated stem cell-derived exosomes as an active ingredient.

[0016] In one embodiment of the present invention, the stem cells may be selected from the group consisting of mesenchymal stem cells, human tissue-derived mesenchymal stromal cells, human tissue-derived mesenchymal stem cells, multipotent stem cells, and amniotic epithelial cells.

[0017] In other embodiments of the invention, the mesenchymal stem cells may be derived from the umbilical cord, umbilical cord blood, bone marrow, fat, muscle, nerve, skin, amniotic membrane, or placenta.

[0018] In still another embodiment of the present invention, the diabetic skin disease may be selected from the group consisting of diabetic ulcer, eruptive xanthomatosis, cutaneous infection, diabetic dermopathy, skin fibroma, acanthosis nigricans, pruritus, scleredema diabeticorum, and granuloma annulare.

[0019] In yet another embodiment of the present invention, the pharmaceutical composition may further comprise an auxiliary component selected from the group consisting of a culture medium, a cytokine, a growth factor, and a gene.

[0020] The present invention also provides a pharmaceutical preparation for treating diabetic skin diseases, comprising the composition.

[0021] In one embodiment of the present invention, the pharmaceutical formulation may be in the form of an injection, infusion, spray, liquid or patch.

[0022] The present invention also provides a quasi-drug preparation for improving diabetic skin diseases, comprising, as an active ingredient, an exosome derived from thrombin-treated stem cells.

[0023] In one embodiment of the present invention, the quasi-drug formulation may be in the form of an external preparation for skin selected from the group consisting of liquids, ointments, creams, sprays, patches, gels, and aerosols.

[0024] The present invention also provides a method for producing said pharmaceutical composition, comprising the steps of: (a) treating the stem cells with thrombin after culturing; (b) isolating exosomes from the culture medium of step (a); and (c) preparing a composition containing the exosomes isolated in step (b) as an active ingredient.

[0025] In one embodiment of the present invention, the thrombin in step (a) may be contained in the medium at a concentration of 1 to 1000 units / ml.

[0026] In another embodiment of the present invention, the exosomes in step (b) may be isolated by centrifugation at 3,000 to 100,000 g for 10 minutes to 5 hours.

[0027] The present invention also provides a method for preventing or treating a diabetic skin disease, comprising administering to an individual a pharmaceutical composition comprising thrombin-treated stem cell-derived exosomes as an active ingredient.

[0028] The present invention also provides a use of the pharmaceutical composition for the prevention or treatment of diabetic skin diseases. Effect of the Invention

[0029] In the present invention, it has been confirmed that exosomes isolated from thrombin-treated stem cells have excellent effects of recovering diabetic skin disorders in diabetic animal models based on specific examples. In addition, since the exosome-based therapeutic agent is a cell-free preparation, it does not contain DNA, so there is little risk of carcinogenesis, and since there is no cell surface antigen, there is no problem of transplant rejection, so it is safe, and since it is an isolated substance rather than a cell, it is possible to develop a drug as an off-the-shelf product, so the manufacturing cost can be reduced. Therefore, it is expected that the exosomes derived from thrombin-treated stem cells according to the present invention can be developed as a therapeutic agent for various intractable chronic skin diseases induced by diabetes, and can be applied to fields related to skin regeneration and be usefully used. [Brief description of the drawings]

[0030] [Figure 1]These are images of exosomes isolated from thrombin-treated stem cells, observed by scanning electron microscope (SEM) and transmission electron microscope (TEM), respectively. [Diagram 2] FIG. 13 shows the results of measuring the levels of exosome markers CD9, CD63 and CD81 via Western blot to confirm that the products isolated from thrombin-treated stem cells are exosomes. [Figure 3a] FIG. 1 shows the results of preparing an animal model in which diabetes was induced to verify the therapeutic effect of thrombin-treated stem cell-derived exosomes on diabetic skin disorders, and shows the average blood glucose levels of a normal group in which saline was intraperitoneally administered to rats (Saline) and a group in which diabetes was induced by intraperitoneally administering streptozotocin (STZ). [Figure 3b] FIG. 13 shows the results of inducing diabetic skin damage and showing no difference in blood glucose among experimental groups administered saline, stem cell-derived exosomes without any treatment (naive exo), and exosomes isolated from thrombin-treated mesenchymal stem cells (thrombin exo). [Figure 4] This figure shows the results of comparing the wound healing effects at 5-day intervals after directly applying saline, untreated stem cell-derived exosomes (naive exo), and exosomes isolated from thrombin-treated mesenchymal stem cells (thrombin exo) to the wound immediately after injuring the back of a diabetes-induced rat model to induce skin damage. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0031] The present inventors have conducted research into the application of exosomes derived from stem cells to the treatment of diabetic skin diseases, and as a result, have confirmed excellent therapeutic effects of the exosomes when skin lesions are induced in a diabetic animal model, as an example of diabetic skin diseases. Based on this, the present inventors have completed the present invention.

[0032] Accordingly, the present invention provides a pharmaceutical composition for preventing or treating diabetic skin diseases, comprising thrombin-treated stem cell-derived exosomes as an active ingredient.

[0033] The term "thrombin" used in the present invention is a proteolytic enzyme involved in blood coagulation, and plays a role in catalyzing the reaction of hydrolyzing soluble fibrinogen in blood to convert it into insoluble fibrin. In the present invention, thrombin is treated with stem cells and the function of exosomes isolated from the stem cells to effectively improve the therapeutic effect of diabetic skin disease is demonstrated.

[0034] The term "stem cell" as used in the present invention refers to an "undifferentiated cell" that has the ability to differentiate but has not yet divided, has the ability to self-replicate, and has the ability to differentiate into two or more different types of cells. The stem cells of the present invention may be autologous or allogeneic stem cells, and may be derived from any type of animal, including humans and non-human mammals.

[0035] In the present invention, the stem cells include embryonic stem cells or adult stem cells, and are preferably adult stem cells. The adult stem cells may be mesenchymal stem cells, human tissue-derived mesenchymal stromal cells, human tissue-derived mesenchymal stem cells, or multipotent stem cells, and are preferably, but not limited to, mesenchymal stem cells.

[0036] The mesenchymal stem cells may be mesenchymal stem cells derived from the umbilical cord, umbilical cord blood, bone marrow, fat, muscle, nerve, skin, amniotic membrane, placenta, etc., and preferably, may be mesenchymal stem cells derived from umbilical cord blood, but are not limited thereto.

[0037] In the present invention, "umbilical cord blood" refers to blood collected from the umbilical vein that connects the placenta and the fetus. Umbilical cord blood is a by-product that occurs naturally during childbirth, and is easier to collect than general mesenchymal tissues such as bone marrow, which require several surgeries. Compared to bone marrow transplantation, the cord blood storage industry has been revitalized and infrastructure has already been established, so it is easy to find donors. In addition, cord blood-derived cells do not express the histocompatibility antigen HLA-DR (class II), which is the most important cause of rejection in tissue and organ transplantation, so that immune reactions such as rejection, which were a problem in conventional transplantation surgery, can be avoided or minimized, and not only autologous cord blood but also allogeneic cord blood can be used.

[0038] The term "exosome" as used herein refers to a small (approximately 30 to 100 nm diameter) membrane-structured vesicle secreted from various cells, and refers to a vesicle released into the extracellular environment by fusion of a multivesicular body with the plasma membrane. The exosome may be naturally secreted or artificially secreted.

[0039] The term "prevention" as used in the present invention means any action of suppressing or delaying the onset of diabetic skin diseases by administering the pharmaceutical composition according to the present invention.

[0040] The term "treatment" as used in the present invention means any action that improves or beneficially alters the symptoms of diabetic skin disease by administration of the pharmaceutical composition according to the present invention.

[0041] In the present invention, "diabetic skin disease" refers to a variety of diseases associated with the skin caused by increased blood sugar due to insulin resistance and abnormal insulin secretion, and specifically may be selected from the group consisting of diabetic ulcer, eruptive xanthomatosis, cutaneous infection, diabetic dermopathy, skin fibroma, acanthosis nigricans, pruritus, scleredema diabeticorum, and granuloma annulare, but is not limited thereto.

[0042] The pharmaceutical composition of the present invention may further comprise an auxiliary component selected from the group consisting of a culture medium, a cytokine, a growth factor, and a gene.

[0043] The pharmaceutical compositions of the present invention can be used alone or in combination with surgery, radiation therapy, hormonal therapy, chemotherapy and biological response modifiers to treat diabetic skin diseases.

[0044] The pharmaceutical composition of the present invention includes exosomes derived from thrombin-treated stem cells as an active ingredient, and may further include a pharma- ceutically acceptable carrier. The pharma-ceutically acceptable carrier is one that is commonly used in formulations, and includes, but is not limited to, saline, sterile water, Ringer's solution, buffered saline, cyclodextrin, dextrose solution, maltodextrin solution, glycerol, ethanol, liposomes, etc., and may further include other common additives such as antioxidants and buffers, as necessary. In addition, the composition may be formulated into an injectable dosage form such as an aqueous solution, suspension, emulsion, pills, capsules, granules, or tablets by additionally adding a diluent, dispersant, surfactant, binder, lubricant, etc. With regard to suitable pharma-ceutically acceptable carriers and formulations, each component may be suitably formulated using the methods disclosed in Remington's literature.

[0045] The pharmaceutical composition of the present invention can be administered orally or parenterally (e.g., intravenously, subcutaneously, intraperitoneally or topically) depending on the intended method, and the dosage varies depending on the condition and weight of the patient, the degree of the disease, the drug form, the administration route and time, but can be appropriately selected by those skilled in the art.

[0046] The pharmaceutical composition of the present invention is administered in a pharma- tically effective amount. In the present invention, the term "pharma- tically effective amount" means an amount sufficient to treat or diagnose a disease with a reasonable benefit / risk ratio applicable to medical treatment or diagnosis, and the effective dose level can be determined by factors including the type and severity of the patient's disease, the activity of the drug, sensitivity to the drug, administration time, administration route and excretion rate, treatment duration, co-used drugs, and other factors well known in the medical field. The pharmaceutical composition according to the present invention can be administered as an individual therapeutic agent or in combination with other therapeutic agents, and can be administered sequentially or simultaneously with conventional therapeutic agents, and can be administered singly or multiple times. It is important to administer an amount that can obtain the maximum effect with the minimum amount without side effects, taking into account all of the above factors, and this can be easily determined by one of ordinary skill in the art.

[0047] Specifically, the effective amount of the pharmaceutical composition of the present invention may vary depending on the age, sex, condition, and weight of the patient, the degree of absorption, inactivation rate, and excretion rate of the active ingredient in the body, the type of disease, and drugs used in combination, and generally, 0.001 to 150 mg, preferably 0.01 to 100 mg per kg of body weight can be administered daily or every other day, or in 1 to 3 divided doses per day. However, since the amount can be increased or decreased depending on the administration route, the severity of obesity, sex, weight, age, etc., the above dosage does not limit the scope of the present invention in any way.

[0048] The present invention also provides a pharmaceutical preparation for treating diabetic skin diseases, comprising the pharmaceutical composition.

[0049] The pharmaceutical preparation may be in the form of an injection, infusion, spray, liquid or patch, but is not limited thereto, and a person skilled in the art can select and use an appropriate dosage form for the treatment of the diabetic skin disease.

[0050] In the present invention, based on specific examples, it has been confirmed that thrombin-treated stem cell-derived exosomes have excellent therapeutic effects on diabetic skin diseases, specifically diabetic skin disorders.

[0051] In one embodiment of the present invention, umbilical cord blood-derived mesenchymal stem cells were treated with thrombin, cultured, and then centrifuged to separate exosomes. The separated exosomes were then observed under a scanning electron microscope and a transmission electron microscope, and the expression levels of exosome-specific markers CD9, CD63, and CD81 were measured to confirm that exosomes were successfully separated (see Example 1).

[0052] In another embodiment of the present invention, prior to evaluating the therapeutic effect of the exosomes on diabetic skin disease, blood glucose was measured in a rat model in which diabetes was induced, and it was confirmed that diabetes was induced more effectively than in a normal group. Accordingly, a diabetic rat model having the same blood glucose level without blood glucose difference was used as a subject, and the skin on the back was scratched to induce skin damage, and then saline, untreated stem cell-derived exosomes, and thrombin-treated stem cell-derived exosomes were treated, and the degree of recovery of the skin damage was evaluated at intervals of 5 days. As a result, it was confirmed that the treatment with the thrombin-treated stem cell-derived exosomes according to the present invention had a significant therapeutic effect (see Example 2).

[0053] Thus, in another aspect, the present invention provides a quasi-drug preparation for improving diabetic skin diseases, comprising exosomes derived from thrombin-treated stem cells as an active ingredient.

[0054] The quasi-drug formulation in the present invention may be in the form of an external preparation for skin selected from the group consisting of liquids, ointments, creams, sprays, patches, gels, and aerosols, and specifically may be used as disinfectants, shower foams, kagrin, wet tissues, detergent soaps, hand washes, humidifier fillers, masks, ointments, or filter filler compositions, but is not limited thereto, and may be appropriately selected and used by those skilled in the art for the improvement of diabetic skin diseases.

[0055] In yet another aspect of the present invention, there is provided a method for producing the pharmaceutical composition, comprising the steps of: (a) treating stem cells with thrombin after culturing; (b) isolating exosomes from the culture medium of step (a); and (c) producing a composition containing the exosomes isolated in step (b) as an active ingredient.

[0056] In the present invention, the concentration of thrombin used for treatment is not particularly limited as long as it is a concentration suitable for enhancing the efficacy of stem cells / exosomes, but it is preferable that thrombin is contained in the medium at a concentration of 1 to 1000 units / ml.

[0057] In the present invention, the method for separating exosomes is not limited, and for example, exosomes can be separated from a culture medium using centrifugation, ultra-high speed centrifugation, filtration with a filter, gel filtration chromatography, free-flow electrophoresis, capillary electrophoresis, separation using a polymer, or a combination thereof, and preferably, centrifugation / ultracentrifugation can be used. In this case, centrifugation / ultracentrifugation is preferably performed at 4°C, 3,000 to 100,000 g for 10 minutes to 5 hours.

[0058] In the present invention, the medium used for cell culture refers to a mixture for the growth and proliferation of cells such as stem cells in vitro, which contains essential elements for cell growth and proliferation, such as sugars, amino acids, various nutrients, serum, growth factors, and minerals. Media that can be used in the present invention include commercially produced media such as DMEM (Dulbecco's Modified Eagle's Medium), MEM (Minimal Essential Medium), BME (Basal Medium Eagle), RPMI1640, DMEM / F-10 (Dulbecco's Modified Eagle's Medium: Nutrient Mixture F-10), DMEM / F-12 (Dulbecco's Modified Eagle's Medium: Nutrient Mixture F-12), α-MEM (α-Minimal essential Medium), G-MEM (Glasgow's Minimal Essential Medium), IMDM (Isocove's Modified Dulbecco's Medium) and KnockOut DMEM, or artificially synthesized media, but are not limited thereto.

[0059] In yet another aspect, the present invention provides a method for preventing or treating a diabetic skin disease, comprising administering to an individual a pharmaceutical composition comprising, as an active ingredient, an exosome derived from thrombin-treated stem cells.

[0060] In the present invention, the term "individual" refers to a subject in need of treatment for a disease, and more specifically refers to mammals such as human or non-human primates, mice, rats, dogs, cats, horses and cows.

[0061] The present invention also provides a use of the pharmaceutical composition for preventing or treating diabetic skin diseases.

[0062] In the following, preferred examples are presented to aid in understanding the present invention. However, the following examples are provided to facilitate understanding of the present invention, and are not intended to limit the scope of the present invention.

[0063] [Example] Example 1. Induction of exosome secretion by thrombin treatment in stem cells Human umbilical cord blood-derived mesenchymal stem cells (3 × 10 5 The cells were then dispensed into 100 mm culture dishes (Orange Scientific Cat# 4450200) and cultured for one week. After confirming that the cells had proliferated to saturation in the culture dishes, the culture medium was replaced with serum-free culture medium (MEM alpha media) in which 50 units / ml of thrombin (REYON Pharmaceutical.Co.,LTD) had been diluted, and the culture medium was further cultured for 6 hours. Thereafter, the culture medium was dispensed into centrifuge tubes and centrifuged at 4°C and 6,000 rpm for 30 minutes, and the supernatant was transferred to a new tube to remove cell debris. The supernatant was then ultracentrifuged at 4°C and 100,000 rpm for 2 to 4 hours, and the supernatant was further removed to obtain exosomes.

[0064] The exosomes isolated by the above process were observed and imaged using a scanning electron microscope (SEM) and a transmission electron microscope (TEM). As a result, as shown in FIG. 1, exosomes secreted by thrombin stimulation through the above method were confirmed.

[0065] In addition, to clearly confirm whether the obtained product was exosome, Western blot was performed to verify the presence or absence of expression of known exosome markers CD9, CD63, and CD81. As a result, as shown in Figure 2, it was shown that the product obtained from thrombin-treated stem cells normally expressed CD9, CD63, and CD81, confirming that the product was exosome.

[0066] Example 2. Verification of the therapeutic effect of thrombin-treated stem cell-derived exosomes on diabetic skin disorders The present inventors conducted the following in vivo experiment to verify whether the exosomes obtained by the method of Example 1 have a therapeutic effect on diabetic chronic skin diseases.

[0067] First, to create an animal model with induced diabetes, 12-16 week old SD rats were intraperitoneally administered 100mg / kg / body of streptozotocin once a day for four days, and blood was collected from the tail for two weeks to measure blood glucose. Only rats with blood glucose levels of 300mg / dL or higher were selected for use in the experiment. As shown in Figure 3a, the normal group used in the experiment had a blood glucose level of 100mg / dL after intraperitoneally administering saline under the same conditions, while the diabetes-induced group had an average blood glucose level of 350mg / dL or higher.

[0068] Then, diabetic skin lesions were induced by injuring the back of the rats with diabetes. Immediately after the injuring, exosomes (naive exo) isolated from untreated mesenchymal stem cells (naive MSC) and exosomes (thrombin exo) isolated from thrombin-treated mesenchymal stem cells were directly applied to the affected area (10ug / rat). Blood glucose levels of rats in each experimental group were measured, and no difference in blood glucose levels was found between the groups, as shown in Figure 3b.

[0069] Thereafter, the area was photographed at five-day intervals to measure changes in the area of ​​the disease and compare the therapeutic effects. As a result, the degree of treatment of skin disorders was significantly higher when treated with thrombin-treated MSC-derived exosomes than when treated with saline or naive MSC-derived exosomes, as shown in Figure 4. These results indicate that exosomes isolated from thrombin-treated MSCs have excellent therapeutic effects on diabetic skin diseases.

[0070] The above description of the present invention is for illustrative purposes only, and those skilled in the art will understand that the present invention can be easily modified into other specific forms without changing the technical concept or essential features of the present invention. Therefore, the above-described embodiments should be understood to be illustrative in all respects and not restrictive. [Industrial Applicability]

[0071] The exosome-based therapeutic agent according to the present invention is a cell-free preparation, and therefore does not contain DNA, so there is little risk of carcinogenesis, and since there is no cell surface antigen, there is no problem of transplant rejection, so it is safe, and since it is an isolated substance rather than a cell, it is possible to develop a drug as an off-the-shelf product, which reduces manufacturing costs. Therefore, it is expected that the thrombin-treated stem cell-derived exosome according to the present invention can be used as a therapeutic agent for various intractable chronic skin diseases induced by diabetes.

Claims

1. A pharmaceutical composition for preventing or treating diabetic dermopathy, comprising an exosome derived from thrombin-treated stem cells as an active ingredient, wherein the stem cells are human umbilical cord blood-derived mesenchymal stem cells.

2. The pharmaceutical composition according to claim 1, further comprising an auxiliary component selected from the group consisting of a culture medium, a cytokine, a growth factor and a gene.

3. A pharmaceutical preparation for treating diabetic dermopathies comprising the composition of claim 1.

4. The pharmaceutical formulation according to claim 3 , wherein the pharmaceutical formulation is in the form of an injection, an infusion, a spray, a liquid or a patch.

5. A quasi-drug formulation for improving diabetic dermopathy, comprising exosomes derived from thrombin-treated stem cells as an active ingredient, wherein the stem cells are human umbilical cord blood-derived mesenchymal stem cells.

6. The quasi-drug formulation according to claim 5, wherein the quasi-drug formulation is in the form of an external preparation for skin selected from the group consisting of a liquid, an ointment, a cream, a spray, a patch, a gel, and an aerosol.

7. A method for producing the pharmaceutical composition of claim 1, comprising the steps of: (a) treating the stem cells with thrombin after culturing; (b) isolating exosomes from the culture medium of step (a); and (c) preparing a composition containing the exosomes isolated in step (b) as an active ingredient.

8. The method according to claim 7, wherein the thrombin in step (a) is contained in the medium at a concentration of 1 to 1000 units / ml.

9. The method of claim 7, wherein the exosomes in step (b) are isolated by centrifugation at 3,000-100,000 g for 10 minutes to 5 hours.

Images